PMID- 19601697
OWN - NLM
STAT- MEDLINE
DCOM- 20090916
LR  - 20181201
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 10
IP  - 11
DP  - 2009 Aug
TI  - Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed 
      combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle 
      glaucoma and ocular hypertension: a 6-month, multicenter, cohort study.
PG  - 1705-11
LID - 10.1517/14656560903061283 [doi]
AB  - PURPOSE: To assess the usefulness and tolerability of systematically switching 
      glaucoma patients from latanoprost 0.005% and timolol 0.5% (Lat + Tim) to a fixed 
      combination of travoprost 0.004%/timolol 0.5% (TTFC), and to record the effects 
      of this switch on tear-film break-up time (TBUT). MAIN OUTCOME MEASURES: 
      Intraocular pressure (IOP) reduction, patients reaching IOP < 18 mmHg; the rate 
      of discontinuation; TBUT; and the onset of adverse events (AEs). METHODS: 
      Multicenter, observational cohort, 6-month study: 309 patients on concomitant Lat 
      + Tim were switched to TTFC (evening dosage). IOP, TBUT, and AEs were recorded at 
      baseline and after 1 and 6 months. RESULTS: IOP was significantly decreased (from 
      18.3 +/- 2.9 to 16.6 +/- 2.7 mmHg) after substitution (p < 0.0001). Many patients 
      (82%) reached an IOP < 18 mmHg (p < 0.0001). TBUT improved significantly (from 
      8.4 +/- 3.6 to 9.2 +/- 3.8 s, p < 0.0001). A few patients reported AEs (8.7%), 
      which caused discontinuation in a low percentage (4.5%). CONCLUSION: TTFC 
      appeared useful in this selected population. In this study, patients who 
      underwent a regimen modification to TTFC obtained further reduction in IOP with a 
      lower exposition to preservative toxicity. The low discontinuation rate at 6 
      months indicates a good tolerability profile.
FAU - Rossi, Gemma Cm
AU  - Rossi GC
AD  - University Eye Clinic of Pavia UO Oculistica, AO Bolognini di Seriate, Italy. 
      gemma.rossi.md@gmail.com
FAU - Pasinetti, Gian Maria
AU  - Pasinetti GM
FAU - Bracchino, Maurizio
AU  - Bracchino M
FAU - Bucarelli, Massimo
AU  - Bucarelli M
FAU - Franchin, Stefano
AU  - Franchin S
FAU - Cerqueti, Piera
AU  - Cerqueti P
FAU - Bellini, Rosa
AU  - Bellini R
FAU - Caravati, Cleofe
AU  - Caravati C
FAU - Celesia, Laura
AU  - Celesia L
FAU - Clemente, Antonella
AU  - Clemente A
FAU - Tinelli, Carmine
AU  - Tinelli C
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Preservatives, Pharmaceutical)
RN  - 0 (Prostaglandins F, Synthetic)
RN  - 4208238832 (Cloprostenol)
RN  - 6Z5B6HVF6O (Latanoprost)
RN  - 817W3C6175 (Timolol)
RN  - WJ68R08KX9 (Travoprost)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antihypertensive Agents/administration & dosage/adverse effects
MH  - Cloprostenol/administration & dosage/adverse effects/*analogs & derivatives
MH  - Cohort Studies
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Glaucoma, Open-Angle/*drug therapy
MH  - Humans
MH  - Intraocular Pressure/drug effects
MH  - Latanoprost
MH  - Male
MH  - Middle Aged
MH  - Ocular Hypertension/drug therapy
MH  - Preservatives, Pharmaceutical/adverse effects
MH  - Prostaglandins F, Synthetic/*administration & dosage/adverse effects
MH  - Tears/drug effects
MH  - Time Factors
MH  - Timolol/*administration & dosage/adverse effects
MH  - Travoprost
EDAT- 2009/07/16 09:00
MHDA- 2009/09/17 06:00
CRDT- 2009/07/16 09:00
PHST- 2009/07/16 09:00 [entrez]
PHST- 2009/07/16 09:00 [pubmed]
PHST- 2009/09/17 06:00 [medline]
AID - 10.1517/14656560903061283 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2009 Aug;10(11):1705-11. doi: 
      10.1517/14656560903061283.